Drug-induced Subacute Cutaneous Lupus Erythematosus.
Case report

Česká verze

Authors: N. Lobotková ¹; H. Tomková ¹; D. Kazakov ²
Authors place of work: Kožní oddělení, Krajská nemocnice Tomáše Bati, a. s. Zlín, primářka MUDr. Hana Tomková, Ph. D., MBA ¹; Bioptická laboratoř Plzeň, s. r. o., odborná vedoucí lékařka prof. MUDr. Alena Skálová, CSc. ²
Published in the journal: Čes-slov Derm, 96, 2021, No. 1, p. 36-39
Category: Kazuistiky

Summary

The authors describe the case of a 72-year-old patient with generalized merging annular manifestations that occurred two months after the start of omeprazole treatment. The histologic examination confirmed „interface“ dermatitis compatible with the diagnosis of drug induced lupus erythematosus. Short course of 60 mg prednison a day and discontinuation of omeprazol led to the regression of skin manifestations. The authors present current knowledge of drug induced lupus erythematosus forms.

Keywords:

subacute cutaneous lupus erythematosus – drug-induced lupus erythematosus – proton-pump inhibitors

Zdroje

1. ADACHI, A., NAGAI, H., HORIKAWA, T. Anti-SS/Ro antibody as a risk factor for fluorouracil-induced drug eruptions showing acral erythema and discoid lupus erythematosus-like lesions. Dermatology, 2007, 214, p. 85–88.

2. BREATHANACH, S. M. Drug reactions. In: Burnss T., Breathnach S., Cox N., Griffiths C. Rook´s Textbook of Dermatology, Oxford: Blackwell Science, 2004, p. 73.1–73.180.

3. CETKOVSKÁ, P. Kožní autoimunitní nemoci indukované léčbou. Čes-slov Derm, 2005, 80, p. 322–325.

4. LAURINAVICIENE, R., SANDHOLDT, L. H, BYGUM, A. Drug induced cutaneous lupus erzthematosus: 88 new cases. Eur J Dermatol, 2017, 27, p. 28–33.

5. MARZANO, A. V., LAZZARI, R., POLLONI, I., CROSTI, C., FABRII, P., CUGNO, M. Drug induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Br J Dermatol, 2011, 165, p. 335–341.

6. MARZANO, A. V., VEZZOLI, P., CROSTI, C. Drug-induced lupus: an update on its dermatologic aspect. Lupus, 2009, 18, p. 935–940.

7. OKON, L. G., WERTH, V. P. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol, 2013, 27, p. 391–404.

8. REED, B. R., HUFF, J. C., JONES, S. K. et al. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med, 1985, 103, p. 49–51.

9. RUBIN, R. L. Drug-induced lupus. Toxicology, 2005, 209, p. 135–147.

10. SANDHOLDT, H. L., LAURINAVICIENE, R., BYGUM, A. Proton pump inhibitor- induced subacute cutaneous lupus erythematosus. Br J Dermatol, 2014, 170, p. 342–351.

11. TOMKOVÁ, H., DRAHOTUSKÁ, Z., POCK, L. Subakutní kožní lupus erythematosus indukovaný spironolaktonem. Čes-slov Derm, 2012, 87, p. 138–140.

12. VEDOVE, C. D., DEL GIGLIO, M., SCHENA, D., GIROLOMONI, G. Drug induced lupus erythematosus. Arch Dermatol Res, 2009, 301, p. 99–105.

13. VEDOVE, C. D., SIMON, C. J., GIROLOMONI, G. Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNF alfa agents. JDDG, 2012, 10, p. 889–897.

14. YOSHIMASU, T., HIROI, A., UEDA, K., FURUKAWA, F. Discoid lupus erythematosus (DLE)-like lesion induced by uracil-tegafur (UFT). Eur J Dermatol, 2001, 11, p. 54–57.